IVIsadora May Vaz

Isadora May Vaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isadora May Vaz has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Cristina Senegaglia

    Core for Cell Technology, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil

    3 shared publications
  • Paulo Roberto Slud Brofman

    Pontifícia Universidade Católica do Paraná, Brazil; Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa, Brazil

    2 shared publications
  • Tamara Borgonovo

    Unidade Laboratório de Análises Clínicas, Complexo Hospital de Clínicas Universidade Federal do Paraná Curitiba Brazil

    2 shared publications
  • Carmen Lucia Kuniyoshi Rebelatto

    Pontifícia Universidade Católica do Paraná (PUC-PR), Curitiba, PR, Brazil

    1 shared publication
  • Carmen Lúcia Kuniyoshi Rebelatto

    Pontifícia Universidade Católica do Paraná, Brazil; Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa, Brazil

    1 shared publication
  • Carmen Lúcia Kuniyoshi Rebelatto

    Core for Cell Technology - School of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná; National Institute of Science and Technology for Regenerative Medicine, INCT-REGENERA;

    1 shared publication

Latest Publications

  • Open Access

    Chromosomal aberrations after induced pluripotent stem cells reprogramming

    by Isadora May Vaz, Tamara Borgonovo, Tais Hanae Kasai-Brunswick, Danúbia Silva dos Santos, Fernanda Cristina Paccola Mesquita, Juliana Ferreira Vasques, Fernanda Gubert, Carmen Lúcia Kuniyoshi Rebelatto, Alexandra Cristina Senegaglia, Paulo Roberto Slud Brofman

    Induced pluripotent stem cells (iPSCs) are generated from adult cells that have been reprogrammed to pluripotency. However, in vitro cultivation and genetic reprogramming increase genetic instability, which could result in chromosomal abnormalities. Maintenance of genetic stability after reprogramming is required for possible experimental and clinical applications. The aim of this study was to analyze chromosomal alterations by using the G-banding karyotyping method applied to 97 samples from 38 iPSC cell lines generated from peripheral blood or Wharton’s jelly. Samples from patients with long QT syndrome, Jervell and Lange-Nielsen syndrome and amyotrophic lateral sclerosis and from normal individuals revealed the following chromosomal alterations: acentric fragments, chromosomal fusions, premature centromere divisions, double minutes, radial figures, ring chromosomes, polyploidies, inversions and trisomies. An analysis of two samples generated from Wharton’s jelly before and after reprogramming showed that abnormal clones can emerge or be selected and generate an altered lineage. IPSC lines may show clonal and nonclonal chromosomal aberrations in several passages (from P6 to P34), but these aberrations are more common in later passages. Many important chromosomal aberrations were detected, showing that G-banding is very useful for evaluating genetic instability with important repercussions for the application of iPSC lines.


  • Open Access

    Emergence of clonal chromosomal alterations during the mesenchymal stromal cell cultivation

    by Tamara Borgonovo, Maria Marlene Solarewicz, Isadora May Vaz, Debora Daga, Carmen Lúcia Kuniyoshi Rebelatto, Alexandra Cristina Senegaglia, Enilze Ribeiro, Iglenir João Cavalli, Paulo Slud Brofman

    Use of human mesenchymal stromal cells (MSCs) is a promising strategy for cell therapy in injured tissues recovery. However, MSCs acquire genetic changes when cultivated in vitro that make them more susceptible to undergo neoplastic transformation. Therefore, genomic integrity of stem cells should be monitored carefully for the use in basic research and clinical trials, including karyotype analysis to confirm the absence of genetic instability. Here, we report a case of a male 67-year-old patient selected to join the study: “Autologous transplantation of mesenchymal cells for treatment of severe and refractory ischemic cardiomyopathy”. He underwent nephrectomy for malignant tumor on the right kidney. Cytogenetic analysis on a bone marrow sample showed a normal karyotype: 46,XY[20]. However, the MSC at second passage showed a hyperdiploid clone, with clonal trisomies of chromosomes 4, 5, 10 and X. In order to investigate more, another sample from the same patient was used for a second cultivation and, at third passage, these cells showed a clonal translocation t(9;18)(p24;q11). The recurrent aberrations in MSC may indicate the beginning of a spontaneous transformation in culture, so, these cells were not used for cell therapy. Several analyses were performed at the Center for Cell Technology (152 samples), however this was the only case to show clonal cytogenetic abnormalities. Interestingly, two distinct clonal alterations were seen in two parallel cell cultivations from the same patient, suggesting a propensity for genetic instability. This highlights the need to evaluate these cells on a case-by-case basis, especially in patients with a history of cancer. Although there is controversy about the use of cells with cytogenetic abnormality for therapy, because their tumorigenic doubtful potential, we decided against the use of these cells for regenerative medicine. Here, we report a case of a male 67-year-old patient selected to join the study: “Autologous transplantation of mesenchymal cells for treatment of severe and refractory ischemic cardiomyopathy”. He underwent nephrectomy for malignant tumor on the right kidney. Cytogenetic analysis on a bone marrow sample showed a normal karyotype: 46,XY[20]. However, the MSC at second passage showed a hyperdiploid clone, with clonal trisomies of chromosomes 4, 5, 10 and X. In order to investigate more, another sample from the same patient was used for a second cultivation and, at third passage, these cells showed a clonal translocation t(9;18)(p24;q11). The recurrent aberrations in MSC may indicate the beginning of a spontaneous transformation in culture, so, these cells were not used for cell therapy. Several analyses were performed at the Center for Cell Technology(152 samples), however this was the only case to show clonal cytogenetic abnormalities. Interestingly, two distinct clonal alterations were seen in two parallel cell cultivations from the same patient, suggesting a propensity for genetic instability. This highlights the need to evaluate these cells on a case-by-case basis, especially in patients with a history of cancer. Although there is controversy about the use of cells with cytogenetic abnormality for therapy, because their tumorigenic doubtful potential, we decided against the use of these cells forregenerative medicine.


  • Open Access

    Genetic evaluation of mesenchymal stem cells by G-banded karyotyping in a Cell Technology Center

    by Tamara Borgonovo, Isadora May Vaz, Alexandra Cristina Senegaglia, Carmen Lucia Kuniyoshi Rebelatto, Paulo Roberto Slud Brofman